| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/15/2004 | US20040009899 Treating dominant disorders |
| 01/15/2004 | US20040009898 Delivery vehicle construct comprising a cargo portion that is preferably a nucleic acid encoding a CFTR, and a u7-peptide portion. |
| 01/15/2004 | US20040009896 Oral lactoferrin in the treatment of respiratory disorders |
| 01/15/2004 | US20040009895 Also stimulating interleukin-18 or GM-CSF by administering lactoferrin |
| 01/15/2004 | US20040009894 Results in correction of cellular calcium handling and enhancement of cardiac contractility to healthy levels. This method can be used for treatment of acute heart failure, cardiogenic shock and congestive heart failure. |
| 01/15/2004 | US20040009893 Ophthalmic lubricating solution adapted for use in lasik surgery |
| 01/15/2004 | US20040009891 Method and composition for treating obesity by targeting cathepsin |
| 01/15/2004 | US20040009604 Plasmid which codes envelop fusogenic membrane protein for treating cell proliferative disorders; antitumor agents; immunotherapy; gene therapy |
| 01/15/2004 | US20040009603 Antiviral vectors |
| 01/15/2004 | US20040009599 Antisense modulation of cellular inhibitor of apoptosis-1 expression |
| 01/15/2004 | US20040009597 Oligonucleotides for controlling protein tyrosine phosphatase receptor type K gene expression activity and treating diabetes, inflammation and cancer; gene expression inhibition; antisense therapy |
| 01/15/2004 | US20040009588 Comprises targeted adenoviral expression vector coding antitumor agent; gene therapy; gene expression inhibition |
| 01/15/2004 | US20040009555 Comprises nucleotide sequences coding gum arabic for use in food processing and cosmetics |
| 01/15/2004 | US20040009553 Comprises nucleotide sequences coding cardiolipin for diagnosis and treatment of lung, heart and respiratory disorders |
| 01/15/2004 | US20040009551 Comprises nucleotide sequences coding peptide antibiotic for treatment of parasitic infection and cell proliferative disorders |
| 01/15/2004 | US20040009550 Export and modification of (poly)peptides in the lantibiotic way |
| 01/15/2004 | US20040009548 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocytes by contacting blood with polypeptide; cancer diagnosis |
| 01/15/2004 | US20040009547 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocytes by contacting blood with polypeptide; cancer diagnosis |
| 01/15/2004 | US20040009546 Compositions and methods for inhibiting microbial adhesion |
| 01/15/2004 | US20040009531 A quantitative analyzing the concentration of peptide with monoclonal antibody produced by the fused cell hybrid; medical diagnosis |
| 01/15/2004 | US20040009510 Single stranded DNA or RNA is enzymatically catalyzing a chemical reaction, cleavaging a predetermined diseased nucleic acid molecule; polymerases |
| 01/15/2004 | US20040009508 RTVP based compositions and methods for the treatment of prostate cancer |
| 01/15/2004 | US20040009505 A pair of genetic engineered primers for the mutagenic amplification, therapeutic treatment |
| 01/15/2004 | US20040009501 Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor |
| 01/15/2004 | US20040009490 Polynucleotides isolated from Lactobacillus rhamnosus, oligonucleotide probes and primers, genetic constructs comprising the polynucleotides, biological materials, including plants, organisms incorporating them |
| 01/15/2004 | US20040009488 Nucleic acids, proteins, and antibodies |
| 01/15/2004 | US20040009480 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 01/15/2004 | US20040009478 Human nucleic acid sequences from prostate tumor tissue |
| 01/15/2004 | US20040009474 Novel human polynucleotides and polypeptides encoded thereby |
| 01/15/2004 | US20040009464 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmacetical compositions containing such compounds |
| 01/15/2004 | US20040009463 Method for PR-39 peptide mediated selective inhibition of IkappaBalpha |
| 01/15/2004 | US20040009231 hGH (human growth hormone) formulations for pulmonary administration |
| 01/15/2004 | US20040009224 Obesity controlling method |
| 01/15/2004 | US20040009217 Therapeutic liposome composition and method |
| 01/15/2004 | US20040009216 Administering liposomes comprising phospholipids and an aqueous layer, said liposomes having specified average diameter; treating various cardiovascular disorders, reducing cholesterol |
| 01/15/2004 | US20040009192 Diagnosis of and vaccination against |
| 01/15/2004 | US20040009191 Inactivated virulence genes |
| 01/15/2004 | US20040009187 Rotavirus subunit vaccine |
| 01/15/2004 | US20040009184 Recombinant intracellular pathogen immunogenic compositions and methods for use |
| 01/15/2004 | US20040009181 Administering to a vertebrate inflicted with the condition a therapeutically effective amount of a peptide which is derived from alpha-melanocyte-stimulating hormone and biologically functional equivalents thereof |
| 01/15/2004 | US20040009180 Transdermal botulinum toxin compositions |
| 01/15/2004 | US20040009177 In particular, amino acid sequences in the respiratory syncytial vorus G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease |
| 01/15/2004 | US20040009176 Treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function |
| 01/15/2004 | US20040009175 TAO protein kinase polypeptides and methods of use therefor |
| 01/15/2004 | US20040009174 Reducing inflammation in smooth muscle tissue in a subject by administering to subject an effective amount of an agent which inhibits OX40 ligand binding to OX40; treatment of asthma |
| 01/15/2004 | US20040009170 Alpha-melanocyte stimulating hormone peptides protection in organ transplantation |
| 01/15/2004 | US20040009169 Administration of agents for the treatment of inflammation |
| 01/15/2004 | US20040009167 Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain; use in preventing or treating a pathogen infection in a cell or organism |
| 01/15/2004 | US20040009165 Lysosomal enzymes and lysosomal enzyme activators |
| 01/15/2004 | US20040009163 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
| 01/15/2004 | US20040009161 Drug screening from polypeptides and/or proteins coded by allelic genes; genetic engineering |
| 01/15/2004 | US20040009156 Synergistic mixtures comprising drugs such as cisplatin and cytoplasmic motor proteins, used as anticarcinogenic agents |
| 01/15/2004 | US20040009152 Materials and methods for prevention and treatment of RNA viral diseases |
| 01/15/2004 | US20040009150 Administering polypeptides homologous to human interleukin sequences or fusion proteins as anticarcinogenic agents |
| 01/15/2004 | US20040009148 Compositions and methods for modifying toxic effects of proteinaceous compounds |
| 01/15/2004 | US20040009147 Administering mixtures of antibodies and tumor necrosis factors, immunosuppressants, antibiotics, antiinflammatory agents, cytokines, angiogenesis inhibitors or fibroblast growth factors; prophylaxis of graft versus host disease |
| 01/15/2004 | US20040009146 Administering mixtures of gene expression vectors comprising cytokines coding sequences, fragments, variants or peptides, to mammals, for prophylaxis of cancer |
| 01/15/2004 | US20040009125 First series of intranasal administration of E-selectin over period of two weeks, followed by a booster administration of E-selectin after at least two weeks from the first administration of E-selectin to minimize brain tissue damage |
| 01/15/2004 | DE10228837A1 Hautkosmetische Zusammensetzung und Verwendung der Zusammensetzung als Hautbräunungsmittel Skin cosmetic composition and use of the composition as a tanning agent |
| 01/15/2004 | DE10228049A1 Flüssige Zubereitung enthaltend Oligopeptide The liquid formulation containing oligopeptides |
| 01/15/2004 | DE10227914A1 Pharmazeutische Zubereitung mit retardierender Wirkstofffreisetzung, Verfahren zu ihrer Herstellung und Verwendung Pharmaceutical formulation having retarded active substance release, methods for their preparation and use |
| 01/15/2004 | DE10227611A1 Verfahren und Vorrichtung zur Vermehrung und Differenzierung von Zellen in Anwesenheit von Wachstumsfaktoren und einer biologischen Matrix oder Trägerstruktur Method and apparatus for proliferation and differentiation of cells in the presence of growth factors and a biological matrix or supporting structure |
| 01/15/2004 | DE10227232A1 Saure Insulinzubereitungen mit verbesserter Stabilität Acidic insulin preparations with improved stability |
| 01/15/2004 | CA2527619A1 Osteoinductive biomaterials |
| 01/15/2004 | CA2494508A1 Nucleic acid compositions for stimulating immune responses |
| 01/15/2004 | CA2493906A1 Therapeutics for diabetes mellitus |
| 01/15/2004 | CA2492010A1 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 01/15/2004 | CA2491972A1 Alpha-melanocyte stimulating hormone peptides protection in organ transplantation |
| 01/15/2004 | CA2491907A1 Oncolytic virus replicating selectively in tumor cells |
| 01/15/2004 | CA2491712A1 New drug combinations based on magnesium salts and fibrinolytics |
| 01/15/2004 | CA2491685A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-prolpylene glycol |
| 01/15/2004 | CA2491682A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | CA2491611A1 Peptides comprising aromatic d-amino acids and methods of use |
| 01/15/2004 | CA2491513A1 Compositions and methods for ligament growth and repair |
| 01/15/2004 | CA2491508A1 Hcv fusion proteins with modified ns3 domains |
| 01/15/2004 | CA2491497A1 Antisense modulation of insulin-like growth factor 2 expression |
| 01/15/2004 | CA2491488A1 Compositions and methods for the diagnosis and treatment of tumor |
| 01/15/2004 | CA2491479A1 Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 01/15/2004 | CA2491478A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | CA2491474A1 Boroproline compound combination therapy |
| 01/15/2004 | CA2491466A1 Methods and compositions relating to isoleucine boroproline compounds |
| 01/15/2004 | CA2491406A1 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | CA2491382A1 Compositions comprising panthetine for the treatment of dyslipidemia |
| 01/15/2004 | CA2491355A1 Controlled release compositions comprising coated pellets having non-uniform coating thicknesses |
| 01/15/2004 | CA2491321A1 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | CA2491178A1 Full-length interferon gamma polypeptide variants |
| 01/15/2004 | CA2491129A1 Central airway administration for systemic delivery of therapeutics |
| 01/15/2004 | CA2491128A1 Treatment for eye disorder |
| 01/15/2004 | CA2491011A1 Cationic linear peptides having antibacterial and/or antifungal properties |
| 01/15/2004 | CA2490714A1 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | CA2490579A1 Methods for specifically inhibiting histone deacetylase-7 and 8 |
| 01/15/2004 | CA2490572A1 Pig binding protein from adipocytes |
| 01/15/2004 | CA2490564A1 Glp-1 and methods for treating diabetes |
| 01/15/2004 | CA2489919A1 Liposomal vaccine |
| 01/15/2004 | CA2489860A1 Use of an antibody against s100a8 or s100a9 as chemotactic factor inhibitor for modulating inflammatory reactions |
| 01/15/2004 | CA2489754A1 .beta.-sheet breaking peptides |
| 01/15/2004 | CA2489588A1 Compositions and methods for the treatment of immune related diseases |
| 01/14/2004 | EP1380645A2 Production in bacteria ad yeast of hemoglobin and analogues thereof |
| 01/14/2004 | EP1380644A1 The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| 01/14/2004 | EP1380594A1 Fibroblast growth factor-10 |